Skip to Main Content

The giant blood plasma processing company Grifols on Monday said it has agreed to buy Alkahest, a Silicon Valley startup founded by Genentech alums that’s betting that proteins in plasma can fight diseases including Alzheimer’s and Parkinson’s.

The planned acquisition is primed to bring new resources and recognition to the quixotic, often controversial search for an elixir for diseases associated with aging.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!